Activities Report and Appendix 4C
Filed with ASX · · 9 pages · English
Summary by 6ix AI
The report highlights progress in a skin cancer trial and promising results from a prostate cancer trial, alongside updates on industry partnerships. Financially, Invion reported cash reserves at the end of the quarter and outlined its cash inflows and outflows, including payments to related parties. The company aims to leverage trial data for further cancer research and has appointed a new Scientific Advisor to guide its clinical programs.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Invion
- Invion Doses First Patient in Phase I/II Skin Cancer Trial
- Consolidation/Split - IVX
- Invion Limited (ASX: IVX) Prostate Cancer Trial Results
- Ph 2 Prostate Cancer Results Strong Safety and 40% Response
- Invion secures funding through an institutional placement
Later from Invion
- Oesophageal Cancer Collaboration and Funding Agreement
- Completion Of Placement to Accelerate Clinical Programs
- Share Purchase Agreement Termination and Tranche Repayment
- Appendix 4C and Quarterly Activities Report - March 2025
- Dosing of 1st Six Patients in Phase I/II Skin Cancer Trial
Follow Invion into a list and get an email when it puts out news.
Follow Invion